Definition of the interacting interfaces of Apobec3G and HIV-1 Vif using MAPPIT mutagenesis analysis

Nucleic Acids Research

Volumn 38, Issue 6, 2009, Pages 1902-1912

  Lavens, Delphine ^a,b   Peelman, Frank ^a,b   van der Heyden, José ^a,b   Uyttendaele, Isabel ^a,b   Catteeuw, Dominiek ^a,b   Verhee, Annick ^a,b   van Schoubroeck, Bertrand ^c   Kurth, Julia ^c   Hallenberger, Sabine ^c   Clayton, Reginald ^c   Tavernier, Jan ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c TIBOTEC BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; VIF PROTEIN; APOBEC3F PROTEIN, HUMAN; APOBEC3G PROTEIN, HUMAN; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; VIF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO TERMINAL SEQUENCE; ARTICLE; BETA SHEET; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIMERIZATION; GENE MUTATION; HUMAN; HUMAN CELL; HYDROGEN BOND; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SITE DIRECTED MUTAGENESIS; TWO HYBRID SYSTEM; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; METABOLISM; STRUCTURAL HOMOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; MAMMALIA;

BINDING SITES; CELL LINE; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; DIMERIZATION; HUMANS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; PROTEIN INTERACTION DOMAINS AND MOTIFS; STRUCTURAL HOMOLOGY, PROTEIN; TWO-HYBRID SYSTEM TECHNIQUES; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77951232792     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkp1154     Document Type: Article

References (52)

1. Sheehy, A.M., Gaddis, N.C., Choi, J.D. and Malim, M.H. (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature, 418, 646-650.
2. Zheng, Y.H., Irwin, D., Kurosu, T., Tokunaga, K., Sata, T. and Peterlin, B.M. (2004) Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol., 78, 6073-6076.
3. Iwatani, Y., Takeuchi, H., Strebel, K. and Levin, J.G. (2006) Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J. Virol., 80, 5992-6002.
4. Navarro, F., Bollman, B., Chen, H., Konig, R., Yu, Q., Chiles, K. and Landau, N.R. (2005) Complementary function of the two catalytic domains of APOBEC3G. Virology, 333, 374-386.
5. Harris, R.S., Bishop, K.N., Sheehy, A.M., Craig, H.M., Petersen-Mahrt, S.K., Watt, I.N., Neuberger, M.S. and Malim, M.H. (2003) DNA deamination mediates innate immunity to retroviral infection. Cell, 113, 803-809.
6. Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L. and Trono, D. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature, 424, 99-103.
7. Zhang, H., Yang, B., Pomerantz, R.J., Zhang, C., Arunachalam, S.C. and Gao, L. (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature, 424, 94-98.
8. Newman, E.N., Holmes, R.K., Craig, H.M., Klein, K.C., Lingappa, J.R., Malim, M.H. and Sheehy, A.M. (2005) Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol., 15, 166-170.
9. Holmes, R.K., Koning, F.A., Bishop, K.N. and Malim, M.H. (2007) APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J. Biol. Chem., 282, 2587-2595
10. Bishop, K.N., Verma, M., Kim, E.Y., Wolinsky, S.M. and Malim, M.H. (2008) APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog., 4, e1000231.
11. Schafer, A., Bogerd, H.P. and Cullen, B.R. (2004) Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology, 328, 163-168.
12. Zennou, V., Perez-Caballero, D., Gottlinger, H. and Bieniasz, P.D. (2004) APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J. Virol., 78, 12058-12061.
13. Khan, M.A., Kao, S., Miyagi, E., Takeuchi, H., Goila-Gaur, R., Opi, S., Gipson, C.L., Parslow, T.G., Ly, H. and Strebel, K. (2005) Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J. Virol., 79, 5870-5874.
14. Mariani, R., Chen, D., Schrofelbauer, B., Navarro, F., Konig, R., Bollman, B., Munk, C., Nymark-McMahon, H. and Landau, N.R. (2003) Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell, 114, 21-31.
15. Stopak, K., de, N.C., Yonemoto, W. and Greene, W.C. (2003) HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell, 12, 591-601.
16. Wiegand, H.L., Doehle, B.P., Bogerd, H.P. and Cullen, B.R. (2004) A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J., 23, 2451-2458.
17. Yu, X., Yu, Y., Liu, B., Luo, K., Kong, W., Mao, P. and Yu, X.F. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science, 302, 1056-1060.
18. Mehle, A., Strack, B., Ancuta, P., Zhang, C., McPike, M. and Gabuzda, D. (2004) Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem., 279, 7792-7798.
19. Malim, M.H. (2009) APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos. Trans. Roy. Soc. Lond B Biol. Sci., 364, 675-687.
20. Chiu, Y.L. and Greene, W.C. (2008) The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu. Rev. Immunol., 26, 317-353.
21. Chiu, Y.L., Soros, V.B., Kreisberg, J.F., Stopak, K., Yonemoto, W. and Greene, W.C. (2005) Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature, 435, 108-114.
22. Chen, K.M., Harjes, E., Gross, P.J., Fahmy, A., Lu, Y., Shindo, K., Harris, R.S. and Matsuo, H. (2008) Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature, 452, 116-119.
23. Holden, L.G., Prochnow, C., Chang, Y.P., Bransteitter, R., Chelico, L., Sen, U., Stevens, R.C., Goodman, M.F. and Chen, X.S. (2008) Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature, 456, 121-124.
24. Harjes, E., Gross, P.J., Chen, K.M., Lu, Y., Shindo, K., Nowarski, R., Gross, J.D., Kotler, M., Harris, R.S. and Matsuo, H. (2009) An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model. J. Mol. Biol., 389, 819-832.
25. Prochnow, C., Bransteitter, R., Klein, M.G., Goodman, M.F. and Chen, X.S. (2007) The APOBEC-2 crystal structure and functional implications for the deaminase AID. Nature, 445, 447-451.
26. Gooch, B.D. and Cullen, B.R. (2008) Functional domain organization of human APOBEC3G. Virology, 379, 118-124.
27. Huthoff, H., Autore, F., Gallois-Montbrun, S., Fraternali, F. and Malim, M.H. (2009) RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog., 5, e1000330.
28. Conticello, S.G., Harris, R.S. and Neuberger, M.S. (2003) The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol., 13, 2009-2013.
29. Huthoff, H. and Malim, M.H. (2007) Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. J. Virol., 81, 3807-3815.
30. Zhang, K.L., Mangeat, B., Ortiz, M., Zoete, V., Trono, D., Telenti, A. and Michielin, O. (2007) Model structure of human APOBEC3G. PLoS ONE, 2, e378.
31. Bulliard, Y., Turelli, P., Rohrig, U.F., Zoete, V., Mangeat, B., Michielin, O. and Trono, D. (2009) Functional analysis and structural modeling of human APOBEC3G reveals the role of evolutionarily conserved elements in HIV-1 and Alu inhibition. J. Virol., 83, 12611-12621.
32. Eyckerman, S., Verhee, A., Van der Heyden, J., Lemmens, I., Ostade, X.V., Vandekerckhove, J. and Tavernier, J. (2001) Design and application of a cytokine-receptor-based interaction trap. Nat. Cell Biol., 3, 1114-1119.
33. Eyckerman, S., Lemmens, I., Lievens, S., Van der Heyden, J., Verhee, A., Vandekerckhove, J. and Tavernier, J. (2002) Design and use of a mammalian protein-protein interaction trap (MAPPIT). Sci. STKE, 2002, L18.
34. Eyckerman, S., Broekaert, D., Verhee, A., Vandekerckhove, J. and Tavernier, J. (2000) Identification of the Y985 and Y1077 motifs as SOCS3 recruitment sites in the murine leptin receptor. FEBS Lett., 486, 33-37.
35. Lemmens, I., Eyckerman, S., Zabeau, L., Catteeuw, D., Vertenten, E., Verschueren, K., Huylebroeck, D., Vandekerckhove, J. and Tavernier, J. (2003) Heteromeric MAPPIT: a novel strategy to study modification-dependent protein-protein interactions in mammalian cells. Nucleic Acids Res., 31, e75.
36. Tavernier, J., Eyckerman, S., Lemmens, I., Van der Heyden, J., Vandekerckhove, J. and Van, O.X. (2002) MAPPIT: a cytokine receptor-based two-hybrid method in mammalian cells. Clin. Exp. Allergy, 32, 1397-1404.
37. Lavens, D., Montoye, T., Piessevaux, J., Zabeau, L., Vandekerckhove, J., Gevaert, K., Becker, W., Eyckerman, S. and Tavernier, J. (2006) A complex interaction pattern of CIS and SOCS2 with the leptin receptor. J. Cell Sci., 119, 2214-2224.
38. Katoh, K., Kuma, K., Toh, H. and Miyata, T. (2005) MAFFT version 5: improvement in accuracy of multiple sequence alignment. Nucleic Acids Res., 33, 511-518.
39. Eswar, N., Eramian, D., Webb, B., Shen, M.Y. and Sali, A. (2008) Protein structure modeling with MODELLER. Methods Mol. Biol., 426, 145-159.
40. Kozak, S.L., Marin, M., Rose, K.M., Bystrom, C. and Kabat, D. (2006) The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules. J. Biol. Chem., 281, 29105-29119.
41. Yu, Y., Xiao, Z., Ehrlich, E.S., Yu, X. and Yu, X.F. (2004) Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin 1912 Nucleic Acids Research, 2010, Vol. 38, No. 6 ligase complex through a novel SOCS box and upstream cysteines. Genes Dev., 18, 2867-2872.
42. Bogerd, H.P., Doehle, B.P., Wiegand, H.L. and Cullen, B.R. (2004) A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc. Natl Acad. Sci. USA, 101, 3770-3774.
43. Schrofelbauer, B., Chen, D. and Landau, N.R. (2004) A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc. Natl Acad. Sci. USA, 101, 3927-3932.
44. Xu, H., Svarovskaia, E.S., Barr, R., Zhang, Y., Khan, M.A., Strebel, K. and Pathak, V.K. (2004) A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc. Natl Acad. Sci. USA, 101, 5652-5657.
45. Mangeat, B., Turelli, P., Liao, S. and Trono, D. (2004) A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J. Biol. Chem., 279, 14481-14483.
46. Shirakawa, K., Takaori-Kondo, A., Yokoyama, M., Izumi, T., Matsui, M., Io, K., Sato, T., Sato, H. and Uchiyama, T. (2008) Phosphorylation of APOBEC3G by protein kinase A regulates its interaction with HIV-1 Vif. Nat. Struct. Mol. Biol., 15, 1184-1191.
47. Wedekind, J.E., Gillilan, R., Janda, A., Krucinska, J., Salter, J.D., Bennett, R.P., Raina, J. and Smith, H.C. (2006) Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits. J. Biol. Chem., 281, 38122-38126.
48. Bennett, R.P., Presnyak, V., Wedekind, J.E. and Smith, H.C. (2008) Nuclear exclusion of the HIV-1 host defense factor APOBEC3G requires a novel cytoplasmic retention signal and is not dependent on RNA binding. J. Biol. Chem., 283, 7320-7327.
49. Stenglein, M.D., Matsuo, H. and Harris, R.S. (2008) Two regions within the amino-terminal half of APOBEC3G cooperate to determine cytoplasmic localization. J. Virol., 82, 9591-9599.
50. Pattyn, E., Lavens, D., Van der Heyden, J., Verhee, A., Lievens, S., Lemmens, I., Hallenberger, S., Jochmans, D. and Tavernier, J. (2008) MAPPIT (MAmmalian Protein-Protein Interaction Trap) as a tool to study HIV reverse transcriptase dimerization in intact human cells. J. Virol. Methods, 153, 7-15.
51. Schrofelbauer, B., Senger, T., Manning, G. and Landau, N.R. (2006) Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J. Virol., 80, 5984-5991.
52. Russell, R.A., Smith, J., Barr, R., Bhattacharyya, D. and Pathak, V.K. (2009) Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J. Virol., 83, 1992-2003.